Logo image of CAPR

CAPRICOR THERAPEUTICS INC (CAPR) Stock Fundamental Analysis

USA - NASDAQ:CAPR - US14070B3096 - Common Stock

6.18 USD
-0.33 (-5.07%)
Last: 11/3/2025, 1:52:38 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CAPR. CAPR was compared to 534 industry peers in the Biotechnology industry. While CAPR has a great health rating, there are worries on its profitability. While showing a medium growth rate, CAPR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CAPR had negative earnings in the past year.
In the past year CAPR has reported a negative cash flow from operations.
CAPR had negative earnings in each of the past 5 years.
CAPR had negative operating cash flow in 4 of the past 5 years.
CAPR Yearly Net Income VS EBIT VS OCF VS FCFCAPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

CAPR has a Return On Assets of -52.39%. This is comparable to the rest of the industry: CAPR outperforms 48.69% of its industry peers.
The Return On Equity of CAPR (-66.66%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -52.39%
ROE -66.66%
ROIC N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
CAPR Yearly ROA, ROE, ROICCAPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

CAPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAPR Yearly Profit, Operating, Gross MarginsCAPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

CAPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CAPR has more shares outstanding
Compared to 5 years ago, CAPR has more shares outstanding
The debt/assets ratio for CAPR has been reduced compared to a year ago.
CAPR Yearly Shares OutstandingCAPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CAPR Yearly Total Debt VS Total AssetsCAPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

CAPR has an Altman-Z score of 2.77. This is not the best score and indicates that CAPR is in the grey zone with still only limited risk for bankruptcy at the moment.
CAPR has a Altman-Z score of 2.77. This is in the better half of the industry: CAPR outperforms 68.35% of its industry peers.
CAPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.77
ROIC/WACCN/A
WACC8.7%
CAPR Yearly LT Debt VS Equity VS FCFCAPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.37 indicates that CAPR has no problem at all paying its short term obligations.
The Current ratio of CAPR (4.37) is comparable to the rest of the industry.
A Quick Ratio of 4.37 indicates that CAPR has no problem at all paying its short term obligations.
CAPR has a Quick ratio of 4.37. This is comparable to the rest of the industry: CAPR outperforms 50.19% of its industry peers.
Industry RankSector Rank
Current Ratio 4.37
Quick Ratio 4.37
CAPR Yearly Current Assets VS Current LiabilitesCAPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for CAPR have decreased strongly by -76.34% in the last year.
Looking at the last year, CAPR shows a very negative growth in Revenue. The Revenue has decreased by -50.69% in the last year.
Measured over the past years, CAPR shows a very strong growth in Revenue. The Revenue has been growing by 85.64% on average per year.
EPS 1Y (TTM)-76.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.86%
Revenue 1Y (TTM)-50.69%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-100%

3.2 Future

CAPR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.40% yearly.
The Revenue is expected to grow by 75.86% on average over the next years. This is a very strong growth
EPS Next Y-85.41%
EPS Next 2Y-23.76%
EPS Next 3Y20.05%
EPS Next 5Y27.4%
Revenue Next Year-92.12%
Revenue Next 2Y151.01%
Revenue Next 3Y86.61%
Revenue Next 5Y75.86%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CAPR Yearly Revenue VS EstimatesCAPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
CAPR Yearly EPS VS EstimatesCAPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CAPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CAPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAPR Price Earnings VS Forward Price EarningsCAPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAPR Per share dataCAPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

CAPR's earnings are expected to grow with 20.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.76%
EPS Next 3Y20.05%

More info and screens

0

5. Dividend

5.1 Amount

CAPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAPRICOR THERAPEUTICS INC

NASDAQ:CAPR (11/3/2025, 1:52:38 PM)

6.18

-0.33 (-5.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-12 2025-11-12
Inst Owners30.53%
Inst Owner Change-1.14%
Ins Owners1.16%
Ins Owner Change0%
Market Cap282.55M
Revenue(TTM)13.39M
Net Income(TTM)-69975700
Analysts83.75
Price Target21.01 (239.97%)
Short Float %32.2%
Short Ratio9.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-41.63%
Min EPS beat(2)-64.08%
Max EPS beat(2)-19.18%
EPS beat(4)1
Avg EPS beat(4)-11.7%
Min EPS beat(4)-64.08%
Max EPS beat(4)40.43%
EPS beat(8)4
Avg EPS beat(8)-14.71%
EPS beat(12)8
Avg EPS beat(12)-5.96%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-36.44%
Min Revenue beat(4)-100%
Max Revenue beat(4)92.08%
Revenue beat(8)4
Avg Revenue beat(8)-10.81%
Revenue beat(12)8
Avg Revenue beat(12)1660.07%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-17.88%
EPS NY rev (1m)0%
EPS NY rev (3m)-129.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-94.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 21.1
P/FCF N/A
P/OCF N/A
P/B 2.69
P/tB 2.69
EV/EBITDA N/A
EPS(TTM)-1.64
EYN/A
EPS(NY)-1.84
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0.29
BVpS2.3
TBVpS2.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.39%
ROE -66.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 207.77%
Cap/Sales 25.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.37
Quick Ratio 4.37
Altman-Z 2.77
F-Score4
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)311.17%
Cap/Depr(5y)361.27%
Cap/Sales(3y)48.94%
Cap/Sales(5y)164.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.86%
EPS Next Y-85.41%
EPS Next 2Y-23.76%
EPS Next 3Y20.05%
EPS Next 5Y27.4%
Revenue 1Y (TTM)-50.69%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-100%
Revenue Next Year-92.12%
Revenue Next 2Y151.01%
Revenue Next 3Y86.61%
Revenue Next 5Y75.86%
EBIT growth 1Y-144.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-132.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-171.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-197.89%
OCF growth 3YN/A
OCF growth 5YN/A

CAPRICOR THERAPEUTICS INC / CAPR FAQ

What is the fundamental rating for CAPR stock?

ChartMill assigns a fundamental rating of 4 / 10 to CAPR.


Can you provide the valuation status for CAPRICOR THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to CAPRICOR THERAPEUTICS INC (CAPR). This can be considered as Overvalued.


What is the profitability of CAPR stock?

CAPRICOR THERAPEUTICS INC (CAPR) has a profitability rating of 1 / 10.


How financially healthy is CAPRICOR THERAPEUTICS INC?

The financial health rating of CAPRICOR THERAPEUTICS INC (CAPR) is 7 / 10.